Biomedical Engineering Reference
In-Depth Information
Product in Market or Clinical
Trial (Company)
Original P/P
Characteristics and Therapeutic Use
Reference
Adagen (Enzon, USA)
Bovine adenosine deamidase
Severe combined immunodeficiency (SCID)
[397]
Oncaspar ® (Enzon, USA)
Asparaginase
Acute lymphoblastic leukemia
[397]
PEG-Intron ® (Schering-Plough/
Enzon)
IFN-2b
Hepatitis C
[398-400]
NEULASTA ® (Amgen/Nektar)
G-CSF
Neutropenia
[401]
PEGASYS ® (Hoffmann-La Roche)
IFN-2a
PEGASYS is a once weekly medication. One study on
PEGylated INF-2a has shown decreased in vitro activity
of conjugation, while its efficacy justified pegylation
during in vivo studies. Effective in hepatitis C
[402]
Macugen ® or Macuverse ® (Pfizer)
Anti-VEGF aptamer (an RNA
oligonucleotide)
Treatment of ocular vascular disease
[403]
Mircera ® (Hoffman-La Roche,
USA)
Epoetin-
Anemia associated with chronic renal failure
[404]
Somavert ® (Pfizer/Nektar)
hGH mutein
Acromegaly
[405]
Cimizia-certolizumab pegol (UCB)
Anti-TNF Fab
Rheumatoid arthritis (RA) and Crohn's disease
[406,407]
PEG-sTNF-RI (amgen)
Soluble TNF-receptor type I
Potential treatment for RA
[408]
Hematide™
Investigational synthetic
peptide, substituted
with PEG. It is a novel
erythropoietic agent, being
an analogue of EPO
Anemia
[409]
CDP860, a humanized, PEGylated
di-Fab' UCB Pharma, Belgium
Antiplatelet-derived growth
factor
Reduces tumor interstitial fluid pressure, and thus increases
the uptake of concomitantly administered drugs, increases
tumor vascularized volume in advanced stage clinical trials
[410]
IFN-1a, BiogenIdec Inc.
IFN-1a
Antiangiogenic in melanoma, clinical trials, Phase III
[411]
MAXY-G34, maxygen
G-CSF
Clinical trials, completed Phase IIa in 2008. Useful in the
treatment of chemotherapy-induced neutropenia
[412]
Search WWH ::




Custom Search